Aktis Oncology, Inc. Common stock (AKTS) is a publicly traded the market company. As of July 21, 2026, AKTS trades at $24.82 with a market cap of $1.38B and a P/E ratio of -12.72. AKTS moved +4.22% today. Year to date, AKTS is +27760.50%; over the trailing twelve months it is flat. Its 52-week range spans $0.03 to $34.19. Analyst consensus is strong buy with an average price target of $35.50. Rallies surfaces AKTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks AKTS insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $24.82 |
| Market Cap | $1.38B |
| P/E Ratio | -12.72 |
| EPS | $-1.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $34.19 |
| 52-Week Low | $0.03 |
| Volume | 80.51K |
| Avg Volume | 0 |
| Revenue (TTM) | $27.38M |
| Net Income | $-167.95M |
| Gross Margin | -2.52% |
6 analysts cover AKTS: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.50.